Overview Financials News + Filings Key Docs Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
|
|
Cadrenal Therapeutics, Inc.
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 08/18/2023 |
8-K
| Quarterly results |
| 08/16/2023 |
8-K
| Shareholder Nominations Pursuant to Exchange Act Rule 14a-11, Other Events, Financial Statements and Exhibits &nbs... |
| 08/10/2023 |
8-K
| Results of Operations and Financial Condition, Financial Statements and Exhibits Interactive Data |
| 07/24/2023 |
8-K
| Quarterly results |
| 07/14/2023 |
8-K
| Quarterly results |
| 05/10/2023 |
8-K
| Results of Operations and Financial Condition, Financial Statements and Exhibits Interactive Data |
| 03/27/2023 |
8-K
| Investor presentation |
| 01/25/2023 |
8-K
| Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Departure of Directors or Certain Office...|
Docs:
|
"UNDERWRITING AGREEMENT",
"COMMON STOCK PURCHASE WARRANT",
"FORM OF INDEMNIFICATION AGREEMENT",
"AMENDMENT TO ASSET PURCHASE AGREEMENT",
"EMPLOYMENT AGREEMENT This Employment Agreement is entered into as of January 24, 2023 by and between Cadrenal Therapeutics, Inc., a Delaware corporation and Matthew K. Szot . Together, Executive and the Company are sometimes referred to as the “ Parties .” Capitalized terms not otherwise defined herein shall have the meanings set forth in Section 9 below. WHEREAS, the Executive currently serves as the Interim Chief Financial Officer of the Company, pursuant to a Consulting Agreement dated May 17, 2022; WHEREAS, the employment relationship hereunder shall be contingent upon and shall commence upon the completion of a public listing of the Company’ s stock on a national stock exchange and terminate as provided for herein; WHEREAS, the Executive shall serve as the Company’ s Chief Financial O...",
"EMPLOYMENT AGREEMENT This Employment Agreement is entered into as of September 21, 2022 by and between Cadrenal Therapeutics, Inc., a Delaware corporation and Douglas Losordo . Together, Executive and the Company are sometimes referred to as the “ Parties .” Capitalized terms not otherwise defined herein shall have the meanings set forth in Section 9 below. WHEREAS, the Executive currently serves as the Interim Chief Medical Officer of the Company, pursuant to a Letter Agreement, effective as of August 8, 2022; WHEREAS, the employment relationship hereunder shall be contingent upon and shall commence upon the completion of a public listing of the Company’ s stock on a national stock exchange and terminate as provided for herein; WHEREAS, the Executive shall serve as the Company’ s Chief Me...",
"PRESS RELEASE ANNOUNCING PRICING OF IPO, DATED JANUARY 20, 2023",
"Cadrenal Therapeutics Granted FDA Fast Track Designation for Tecarfarin for Prevention of Systemic Thromboembolism of Cardiac Origin in Patients with End-Stage Renal Disease and Atrial Fibrillation PONTE VEDRA, Fla., Jan. 23, 2023 /PRNewswire/ -- Cadrenal Therapeutics , a biopharmaceutical company focused on developing tecarfarin, a clinical stage novel cardiorenal therapy with orphan drug designation, announced today that the U.S. Food and Drug Administration has granted a Fast Track designation to tecarfarin for the prevention of systemic thromboembolism, more commonly referred to as blood clots, of cardiac origin in patients with end-stage renal disease and atrial fibrillation . Fast Track is a process designed to facilitate the development and expedite the review of drugs to treat seri...",
"PRESS RELEASE ANNOUNCING CLOSING OF IPO, DATED JANUARY 24, 2023" |
|
|
|